Keyphrases
Intracranial Pressure
100%
Idiopathic Intracranial Hypertension
100%
Rodents
36%
Increased Intracranial Pressure
36%
Pathophysiology
18%
Obesity
18%
New Drug Targets
18%
Intracranial Pressure Monitoring
18%
Preclinical Research
18%
Therapeutic Potential
9%
A1 Receptor
9%
Anesthesia
9%
Receptor Agonist
9%
Topiramate
9%
Reduction Effect
9%
Glucagon-like
9%
Acetazolamide
9%
Brain Disorders
9%
Molecular Mechanism
9%
Unknown Cause
9%
Pressure Regulation
9%
Common Risk Factors
9%
Drug Target
9%
Pressure Measurement System
9%
Brain Fluids
9%
Intracranial Pressure Measurement
9%
Cerebrospinal Fluid Dynamics
9%
Existing Drugs
9%
Hypertension Development
9%
Short-term Monitoring
9%
Dynamic Molecular
9%
Medicine and Dentistry
Idiopathic Intracranial Hypertension
100%
Intracranial Pressure
100%
Pathophysiology
18%
Disease
18%
Intracranial Pressure Monitoring
18%
Glucagon-Like Peptide-1 Agonist
9%
Brain Disease
9%
Cerebrospinal Fluid
9%
Acetazolamide
9%
Topiramate
9%
Pharmacology, Toxicology and Pharmaceutical Science
Idiopathic Intracranial Hypertension
100%
Pathophysiology
18%
Disease
18%
Topiramate
9%
Acetazolamide
9%
Glucagon Like Peptide 1 Receptor Agonist
9%
Brain Disease
9%
Neuroscience
Idiopathic Intracranial Hypertension
100%
In Vivo
18%
Intracranial Pressure Monitoring
18%
Acetazolamide
9%
Glucagon-Like Peptide-1 Agonist
9%
Topiramate
9%